AstraZeneca to Acquire Icosavax for $1.1 Billion
Deal includes access to experimental vaccines targeting respiratory diseases, with closing expected in Q1 2024.
- AstraZeneca has agreed to acquire US-based vaccine developer Icosavax for $1.1 billion, gaining access to experimental vaccines targeting common respiratory disease-causing viruses.
- The deal includes an upfront cash offer of $15.00 per share for Icosavax, along with an additional contingent value right of $5 per share if its experimental shots meet certain regulatory and sales milestones.
- Icosavax is currently testing a vaccine candidate called IVX-A12, designed to target both Respiratory Syncytial Virus (RSV) and human metapneumovirus (hMPV).
- Phase-II trial data for IVX-A12 showed that it elicits robust immune responses against both RSV and hMPV one month after vaccination.
- The acquisition is expected to close in the first quarter of 2024.
Investopedia 
The Telegraph 
GeekWire 
Benzinga 
The Guardian 
Barron's 
Reuters 
Forbes 
